Showing results (261-270 of 340) with videos related to
Sort By:
Pageof 34
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|February 16, 2012
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)Hans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.Kidney International|February 14, 2014
Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similarChi Pang Wen, Kunihiro Matsushita, Josef Coresh, et al.Journal of the American Society of Nephrology : JASN|September 23, 2021
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR TrialHiddo J L Heerspink, Di Xie, George Bakris, et al.Diabetologia|August 27, 2021
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS ProgramTamara K Young, Jing-Wei Li, Amy Kang, et al.Circulation|October 3, 2002
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general populationHans L Hillege, Vaclav Fidler, Gilles F H Diercks, et al.ESC Heart Failure|November 8, 2016
Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population-based cohort studyLaura M G Meems, Frank P Brouwers, Michel M Joosten, et al.Heart (British Cardiac Society)|July 24, 2012
Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general populationFrank P Brouwers, Rudolf A de Boer, Pim van der Harst, et al.Kidney International Reports|June 15, 2026
Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension StatusRicardo Correa-Rotter, Peter Rossing, Maria Eugenia Canziani, et al.Clinical Chemistry|September 28, 2011
Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular eventsKornelis J J van Hateren, Alaa Alkhalaf, Nanne Kleefstra, et al.Current Medical Research and Opinion|November 2, 2006
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertensionAndrew J Palmer, William J Valentine, Daniel M D Tucker, et al.Pageof 34